Acusphere(OTC) ACUS

Acusphere, Inc. is a pharmaceutical company focused on developing and commercializing innovative cardiovascular treatments. The company's flagship product, Imagify, is designed to assess myocardial perfusion and assist in diagnosing coronary artery disease.

Products and Services

• Imagify: A cardiovascular medication for myocardial perfusion assessment
• Injectable suspension formulation for enhanced delivery
• Research and development of additional cardiovascular therapies

Growth Outlook

• Continued focus on expanding the cardiovascular treatment market
• Potential for new product launches in the pipeline
• Strategic partnerships to enhance market reach and capabilities

Financial Highlights

• Recent quarterly revenue of 339,000, showing product demand
• Operating income margin of 29.31%, indicating operational efficiency
• Cash and cash equivalents of 4,112,000, providing liquidity for operations

Acusphere, Inc. operates within the healthcare sector, specifically in the drug manufacturing industry, with a focus on specialty and generic drugs. The company has a history of innovation, having been established in 1993 and rebranded in 2004. The headquarters is located in Watertown, Massachusetts, and the company employs approximately 50 individuals. The financial performance indicates a commitment to research and development, with significant investments in this area. The recent quarterly results reflect a revenue stream that, while modest, demonstrates the potential for growth in the cardiovascular market. The operating income margin suggests that the company is managing its expenses effectively, which is crucial for long-term sustainability. With a solid cash position, Acusphere is well-positioned to navigate the challenges of the pharmaceutical industry. The focus on cardiovascular treatments aligns with growing healthcare needs, making it an intriguing option for investors interested in the healthcare sector.